Literature DB >> 24917417

Transamidation of gluten proteins during the bread-making process of wheat flour to produce breads with less immunoreactive gluten.

Nina Gisella Heredia-Sandoval1, Alma Rosa Islas-Rubio, Francisco Cabrera-Chávez, Ana María Calderón de la Barca.   

Abstract

Due to an increasing incidence of celiac disease (CD) and other gluten-related disorders, different gluten-free breads have been developed using starches and additives as a substitute for gluten. Thus, patients miss not only the taste and aroma of wheat bread but also risk their sensitive intestines. Therefore, modifying gluten to avoid an immune response in CD and its application to baking is in progress. The aim of the study was to enzymatically modify gluten on wheat flour, during bread-making avoiding the use of additives, to reduce immunoreactivity, preserving its properties. Microbial transglutaminase (mTG) or chymotrypsin (ChT) was used to bind lysine or valine to gluten proteins in a model system. The best conditions were directly applied to wheat flour for bread-making with and without punching at 45 min. Subsequently, the rheological properties of the doughs, specific volume of the loaves, immunoreactive gluten content and modification of the extracted proteins were evaluated. ChT-treated breads presented a better appearance with a more homogeneous crumb, higher specific volume values (3.34-4.25 cm(3) g(-1)) and higher reactive gluten reduction (up to 71%) than the mTG-treated ones (1.23-2.66 cm(3) g(-1)) with only a 42% reactive gluten reduction. Thus, transpeptidation during bread-making is a promising technology, although it is necessary to improve the modification process to obtain the reactive gluten reduction required in breads for the treatment of CD patients and other gluten-related disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24917417     DOI: 10.1039/c4fo00118d

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  7 in total

1.  Wheat-induced food allergy in childhood: ancient grains seem no way out.

Authors:  Steven Sievers; Alexander Rohrbach; Kirsten Beyer
Journal:  Eur J Nutr       Date:  2019-10-25       Impact factor: 5.614

2.  Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis.

Authors:  Aaron Lerner; Torsten Matthias
Journal:  Nutr Rev       Date:  2015-06-16       Impact factor: 7.110

3.  Efficient chemo-enzymatic gluten detoxification: reducing toxic epitopes for celiac patients improving functional properties.

Authors:  Miguel Ribeiro; Fernando M Nunes; Sofia Guedes; Pedro Domingues; Amélia M Silva; Jose Maria Carrillo; Marta Rodriguez-Quijano; Gérard Branlard; Gilberto Igrejas
Journal:  Sci Rep       Date:  2015-12-22       Impact factor: 4.379

4.  Abrogation of Immunogenic Properties of Gliadin Peptides through Transamidation by Microbial Transglutaminase Is Acyl-Acceptor Dependent.

Authors:  Lin Zhou; Yvonne M C Kooy-Winkelaar; Robert A Cordfunke; Irina Dragan; Allan Thompson; Jan Wouter Drijfhout; Peter A van Veelen; Hongbing Chen; Frits Koning
Journal:  J Agric Food Chem       Date:  2017-08-17       Impact factor: 5.279

5.  Tissue Transglutaminase but Not Microbial Transglutaminase Is Inhibited by Exogenous Oxidative Substances in Celiac Disease.

Authors:  Sebastian Stricker; Silvia Rudloff; Jan De Laffolie; Klaus-Peter Zimmer
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

6.  The evaluation of part-baked frozen bread produced from wheat flour and guar gum in the diet of celiac patients.

Authors:  Toktam Hejrani; Zahra Sheikholeslami; S Ali Mortazavi; Mahdi Karimi; Amir Hosesein Elhamirad
Journal:  J Food Sci Technol       Date:  2020-09-02       Impact factor: 3.117

Review 7.  Processed Food Additive Microbial Transglutaminase and Its Cross-Linked Gliadin Complexes Are Potential Public Health Concerns in Celiac Disease.

Authors:  Aaron Lerner; Torsten Matthias
Journal:  Int J Mol Sci       Date:  2020-02-08       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.